These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 12871554)
1. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. Colman RW; Pixley RA; Sainz IM; Song JS; Isordia-Salas I; Muhamed SN; Powell JA; Mousa SA J Thromb Haemost; 2003 Jan; 1(1):164-70. PubMed ID: 12871554 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of angiogenesis by a monoclonal antibody to kininogen as well as by kininostatin which block proangiogenic high molecular weight kininogen. Colman RW Int Immunopharmacol; 2002 Dec; 2(13-14):1887-94. PubMed ID: 12489802 [TBL] [Abstract][Full Text] [Related]
3. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Colman RW; Jameson BA; Lin Y; Johnson D; Mousa SA Blood; 2000 Jan; 95(2):543-50. PubMed ID: 10627460 [TBL] [Abstract][Full Text] [Related]
4. The contact system and angiogenesis: potential for therapeutic control of malignancy. Colman RW Semin Thromb Hemost; 2004 Feb; 30(1):45-61. PubMed ID: 15034797 [TBL] [Abstract][Full Text] [Related]
5. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Zhang JC; Donate F; Qi X; Ziats NP; Juarez JC; Mazar AP; Pang YP; McCrae KR Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12224-9. PubMed ID: 12196635 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Song JS; Sainz IM; Cosenza SC; Isordia-Salas I; Bior A; Bradford HN; Guo YL; Pixley RA; Reddy EP; Colman RW Blood; 2004 Oct; 104(7):2065-72. PubMed ID: 15161672 [TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Espinola RG; Uknis A; Sainz IM; Isordia-Salas I; Pixley R; DeLa Cadena R; Long W; Agelan A; Gaughan J; Adam A; Colman RW Am J Pathol; 2004 Sep; 165(3):969-76. PubMed ID: 15331420 [TBL] [Abstract][Full Text] [Related]
8. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. Guo YL; Colman RW J Thromb Haemost; 2005 Apr; 3(4):670-6. PubMed ID: 15733059 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of metastasis of syngeneic murine melanoma in vivo and vasculogenesis in vitro by monoclonal antibody C11C1 targeted to domain 5 of high molecular weight kininogen. Khan ST; Pixley RA; Liu Y; Bakdash N; Gordon B; Agelan A; Huang Y; Achary MP; Colman RW Cancer Immunol Immunother; 2010 Dec; 59(12):1885-93. PubMed ID: 20811885 [TBL] [Abstract][Full Text] [Related]
10. Regulation of angiogenesis by the kallikrein-kinin system. Colman RW Curr Pharm Des; 2006; 12(21):2599-607. PubMed ID: 16842160 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Kumar CC; Malkowski M; Yin Z; Tanghetti E; Yaremko B; Nechuta T; Varner J; Liu M; Smith EM; Neustadt B; Presta M; Armstrong L Cancer Res; 2001 Mar; 61(5):2232-8. PubMed ID: 11280792 [TBL] [Abstract][Full Text] [Related]
12. Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. Ribatti D; Nico B; Morbidelli L; Donnini S; Ziche M; Vacca A; Roncali L; Presta M J Vasc Res; 2001; 38(4):389-97. PubMed ID: 11455210 [TBL] [Abstract][Full Text] [Related]
13. Kininostatin as an antiangiogenic inhibitor: what we know and what we do not know. Guo YL; Wang S; Colman RW Int Immunopharmacol; 2002 Dec; 2(13-14):1931-40. PubMed ID: 12489806 [TBL] [Abstract][Full Text] [Related]
14. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. Zhang JC; Claffey K; Sakthivel R; Darzynkiewicz Z; Shaw DE; Leal J; Wang YC; Lu FM; McCrae KR FASEB J; 2000 Dec; 14(15):2589-600. PubMed ID: 11099478 [TBL] [Abstract][Full Text] [Related]
15. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903 [TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic activity of the purine analog 6-thioguanine. Presta M; Belleri M; Vacca A; Ribatti D Leukemia; 2002 Aug; 16(8):1490-9. PubMed ID: 12145690 [TBL] [Abstract][Full Text] [Related]
17. The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases. Liu Y; Sainz IM; Wu Y; Pixley R; Espinola RG; Hassan S; Khan MM; Colman RW Exp Cell Res; 2008 Feb; 314(4):774-88. PubMed ID: 18062965 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5. McCrae KR; Doñate F; Merkulov S; Sun D; Qi X; Shaw DE Curr Cancer Drug Targets; 2005 Nov; 5(7):519-28. PubMed ID: 16305348 [TBL] [Abstract][Full Text] [Related]
19. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. Bråkenhielm E; Cao R; Cao Y FASEB J; 2001 Aug; 15(10):1798-800. PubMed ID: 11481234 [No Abstract] [Full Text] [Related]
20. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Khan MM; Bradford HN; Isordia-Salas I; Liu Y; Wu Y; Espinola RG; Ghebrehiwet B; Colman RW Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2260-6. PubMed ID: 16902163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]